Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Odetiglucan in Liver-Predominant Metastatic Colorectal Cancer
NCT07082439Phase 2Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of odetiglucan in colorectal adenocarcinoma, sponsored by Abramson Cancer Center. Primary endpoint: Overall response rate up to 2 years. Started Sep 2025; status: recruiting.
02
Drugs
odetiglucan
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT07082439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082439.